Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir

被引：11

作者：

Cicconi, P ^{[1
]}

Bongiovanni, A ^{[1
]}

Melzi, S ^{[1
]}

Tordato, F ^{[1
]}

Monforte, AD ^{[1
]}

Bini, T ^{[1
]}

机构：

[1] Luigi Sacco Hosp, Inst Infect & Trop Dis, I-20157 Milan, Italy

来源：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2004年 / 24卷 / 03期

关键词：

HIV; tenofovir; nephrolithiasis;

D O I：

10.1016/j.ijantimicag.2004.04.005

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The use of tenofovir as part of a HAART regimen has been widely used in HIV-multi-experienced-patients because of its favourable resistance profile. Tenofovir is mainly eliminated by the kidneys and renal toxicity should be carefully monitored. We describe here the case of an HIV-infected patient, without a prior history of renal failure who developed nephrolithiasis and hydronephrosis after starting a tenofovir-containing HAART regimen. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

引用

页码：284 / 285

页数：2

共 8 条

[1] Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs [J].

Cihlar, T ;

Ho, ES ;

Lin, DC ;

Mulato, AS .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :641-648

[2] Renal lesions in HIV-1-positive patient treated with tenofovir [J].

Créput, C ;

Gonzalez-Canali, G ;

Hill, G ;

Piketty, C ;

Kazatchkine, M ;

Nochy, D .

AIDS, 2003, 17 (06) :935-937

[3]

Dobkin JF, 2002, INFECT MED, V19, P11

[4]

*GIL SCI, 2001, VIR TEN DIS FUM PACK

[5] Fatal lactic acidosis and acute renal failure after addition of tenofovir to an Antiretroviral regimen containing Didanosine [J].

Murphy, MD ;

O'Hearn, M ;

Chou, SW .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (08) :1082-1085

[6] Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study [J].

Schooley, RT ;

Ruane, P ;

Myers, RA ;

Beall, G ;

Lampiris, H ;

Berger, D ;

Chen, SS ;

Miller, MD ;

Isaacson, E ;

Cheng, AK .

AIDS, 2002, 16 (09) :1257-1263

[7] EMERGENCE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 VARIANTS WITH RESISTANCE TO MULTIPLE DIDEOXYNUCLEOSIDES IN PATIENTS RECEIVING THERAPY WITH DIDEOXYNUCLEOSIDES [J].

SHIRASAKA, T ;

KAVLICK, MF ;

UENO, T ;

GAO, WY ;

KOJIMA, E ;

ALCAIDE, ML ;

CHOKEKIJCHAI, S ;

ROY, BM ;

ARNOLD, E ;

YARCHOAN, R ;

MITSUYA, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (06) :2398-2402

[8]

Wainberg MA, 1999, ANTIVIR THER, V4, P87

← 1 →